Physician profile
Bryan D Cheever
NPI 1063459220
$5,310.85
in general payments reported to CMS, 2019-2025
38 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,034 · 2020: $993 · 2021: $815 · 2022: $438 · 2023: $411 · 2024: $233 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $561.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $517.49 | 2019-2024 | Farxiga |
| Abbvie INC. | $392.12 | 2019-2023 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $382.03 | 2019-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.68 | 2019-2022 | |
| Pfizer INC. | $327.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $290.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $258.30 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $216.56 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $206.33 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.63 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.33 | 2019-2023 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $165.46 | 2019-2022 | |
| Mylan Specialty L.P. | $162.91 | 2019-2024 | Yupelri |
| Amarin Pharma, INC. | $115.26 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Cheever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.